Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration

Leptomeningeal disease (LMD) is a devastating complication of cancer, and its incidence is rising. The inaugural LMD Think Tank Meeting took place in 2023 during the Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) annual meeting, convening an international group of clinicians and scientists dedicated to understanding and treating LMD in a multidisciplinary fashion. While this meeting laid the foundation for a SNO/ASCO consensus review on the clinical management of LMD, the frequent exclusion of LMD patients from trials was identified as a clear and pervasive challenge. To address this gap, a follow up assembly convened in 2024 with a goal of developing a SNO/ASCO consensus on best practices for clinical research; this included addressing the role of industry and basic scientists in clinical trials, providing guidance for improved clinical trial design, and accelerating the enrollment of LMD patients into clinical trials. Academic-industry partnerships and multi-institutional collaborations are crucial to advance our understanding of LMD, expand treatment access, and ultimately, improve survival and quality of life for our patients.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2026-05-27
DOI
https://doi.org/10.1093/neuonc/noag126
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration

Susan Chang, Melanie Hayden Gephart, Eudocia Q. Lee, Ján Remšík et al.
Neuro-Oncology
Brain Metastases and Treatment
article

Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration

Susan Chang, Melanie Hayden Gephart, Eudocia Q. Lee, Ján Remšík, P. Kumthekar, Yolanda Pina, Inna Smalley, Maxine Umeh Garcia, A. Boire, Barbara O’Brien, Michael Weller, Jeffrey Wefel, Elena Pentsova, Isabella C Glitza Oliva, Emilie Le Rhun, Peter A.J. Forsyth, Andrew Brenner, Jonathan T Yang, David Olayinka Kamson, Seema Nagpal, D Ross Camidge, Jessica Wilcox, David Piccioni
article en

Abstract

Leptomeningeal disease (LMD) is a devastating complication of cancer, and its incidence is rising. The inaugural LMD Think Tank Meeting took place in 2023 during the Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) annual meeting, convening an international group of clinicians and scientists dedicated to understanding and treating LMD in a multidisciplinary fashion. While this meeting laid the foundation for a SNO/ASCO consensus review on the clinical management of LMD, the frequent exclusion of LMD patients from trials was identified as a clear and pervasive challenge. To address this gap, a follow up assembly convened in 2024 with a goal of developing a SNO/ASCO consensus on best practices for clinical research; this included addressing the role of industry and basic scientists in clinical trials, providing guidance for improved clinical trial design, and accelerating the enrollment of LMD patients into clinical trials. Academic-industry partnerships and multi-institutional collaborations are crucial to advance our understanding of LMD, expand treatment access, and ultimately, improve survival and quality of life for our patients.

Neuro-Oncology
Northwestern University (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Johns Hopkins University (US), University of San Diego (US), The University of Texas at San Antonio Health Science Center (US), Cornell University (US), Johns Hopkins Medicine (US), UC San Diego Health System (US), Moffitt Cancer Center (US), VIB-KU Leuven Center for Cancer Biology (BE), University Hospital of Zurich (CH), Dana-Farber Cancer Institute (US), Stanford Medicine (US), Neurological Surgery (US), University of California Davis Medical Center (US), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Colorado Anschutz Medical Campus (US), New York University (US), University of California, Davis (US), Stanford University (US), KU Leuven (BE)
Partnerships for the goals
Openalex Percentile: Top 8%
Brain Metastases and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.